Literature DB >> 12181416

Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.

Gisela Barbany, Martin Höglund, Bengt Simonsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12181416     DOI： 10.1056/NEJM200208153470719

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Authors:  Maria Schwaederle; Barbara A Parker; Richard B Schwab; Paul T Fanta; Sarah G Boles; Gregory A Daniels; Lyudmila A Bazhenova; Rupa Subramanian; Alice C Coutinho; Haydee Ojeda-Fournier; Brian Datnow; Nicholas J Webster; Scott M Lippman; Razelle Kurzrock
Journal:  Oncologist       Date:  2014-05-05

Review 2.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Authors:  Maria Schwaederle; Melissa Zhao; J Jack Lee; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 3.  Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment.

Authors:  Anne Poder Andersen; José M A Moreira; Stine Falsig Pedersen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-02-03       Impact factor: 6.237

4.  c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice.

Authors:  Rong Wu; Jian-Guang Sun; Ji-Qiu Wang; Binhua Li; Qingsong Liu; Guang Ning; Wanzhu Jin; Zengqiang Yuan
Journal:  Diabetologia       Date:  2017-01-10       Impact factor: 10.122

Review 5.  Personalized medicine and cancer.

Authors:  Mukesh Verma
Journal:  J Pers Med       Date:  2012-01-30

6.  Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.

Authors:  Miao Gao; Zheng-Lan Huang; Kun Tao; Qing Xiao; Xin Wang; Wei-Xi Cao; Min Xu; Jing Hu; Wen-Li Feng
Journal:  Oncotarget       Date:  2017-01-10

7.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12

8.  Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Authors:  Maria Schwaederle; Hatim Husain; Paul T Fanta; David E Piccioni; Santosh Kesari; Richard B Schwab; Kimberly C Banks; Richard B Lanman; AmirAli Talasaz; Barbara A Parker; Razelle Kurzrock
Journal:  Oncotarget       Date:  2016-03-01

9.  A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.

Authors:  A Collignon; M A Hospital; C Montersino; F Courtier; A Charbonnier; C Saillard; E D'Incan; B Mohty; A Guille; J Adelaïde; N Carbuccia; S Garnier; M J Mozziconacci; C Zemmour; J Pakradouni; A Restouin; R Castellano; M Chaffanet; D Birnbaum; Y Collette; N Vey
Journal:  Blood Cancer J       Date:  2020-06-03       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.